Deprescribing for People with Dementia: A Roadmap.

IF 3.8 3区 医学 Q2 GERIATRICS & GERONTOLOGY
Drugs & Aging Pub Date : 2025-09-01 Epub Date: 2025-08-26 DOI:10.1007/s40266-025-01238-w
Ariel R Green, Cynthia M Boyd, Rosalphie Quiles, Andrea E Daddato, Kathy Gleason, Tobie Taylor-McPhail, Aleksandra Wec, Stephanie K Nothelle, Rebecca S Boxer
{"title":"Deprescribing for People with Dementia: A Roadmap.","authors":"Ariel R Green, Cynthia M Boyd, Rosalphie Quiles, Andrea E Daddato, Kathy Gleason, Tobie Taylor-McPhail, Aleksandra Wec, Stephanie K Nothelle, Rebecca S Boxer","doi":"10.1007/s40266-025-01238-w","DOIUrl":null,"url":null,"abstract":"<p><p>People with dementia (PWD) are frequently exposed to polypharmacy and potentially inappropriate medication use, in which the risks of medication use outweigh the benefits or the medication is not aligned with treatment goals. Appropriate deprescribing of unnecessary or potentially inappropriate medications is essential to high-quality care for PWD, to avoid iatrogenic harm and improve health and well-being for patients and their care partners. In this article, we review the risks of polypharmacy in PWD and evidence for the safety and efficacy of deprescribing in this population. Building off existing deprescribing frameworks for older adults with multimorbidity and limited life expectancy, we provide a roadmap for deprescribing in PWD that addresses the unique challenges of living dementia, including the variable disease course, high prevalence of distressing behavioral symptoms, and central role of care partners. The steps include: (1) identify potential targets for deprescribing by eliciting medication-related goals and considering tradeoffs, (2) develop a tapering plan, (3) complete additional actions that are necessary before deprescribing, and (4) provide close follow-up. Lastly, we provide evidence-based strategies for communicating with patients and their care partners about deprescribing, adapted from the FRAME tool.</p>","PeriodicalId":11489,"journal":{"name":"Drugs & Aging","volume":" ","pages":"795-806"},"PeriodicalIF":3.8000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12436473/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs & Aging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40266-025-01238-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

People with dementia (PWD) are frequently exposed to polypharmacy and potentially inappropriate medication use, in which the risks of medication use outweigh the benefits or the medication is not aligned with treatment goals. Appropriate deprescribing of unnecessary or potentially inappropriate medications is essential to high-quality care for PWD, to avoid iatrogenic harm and improve health and well-being for patients and their care partners. In this article, we review the risks of polypharmacy in PWD and evidence for the safety and efficacy of deprescribing in this population. Building off existing deprescribing frameworks for older adults with multimorbidity and limited life expectancy, we provide a roadmap for deprescribing in PWD that addresses the unique challenges of living dementia, including the variable disease course, high prevalence of distressing behavioral symptoms, and central role of care partners. The steps include: (1) identify potential targets for deprescribing by eliciting medication-related goals and considering tradeoffs, (2) develop a tapering plan, (3) complete additional actions that are necessary before deprescribing, and (4) provide close follow-up. Lastly, we provide evidence-based strategies for communicating with patients and their care partners about deprescribing, adapted from the FRAME tool.

Abstract Image

Abstract Image

痴呆症患者的处方处方:路线图。
痴呆症患者经常面临多种用药和可能不适当的药物使用,其中药物使用的风险大于益处或药物与治疗目标不一致。适当开不必要的或可能不适当的药物处方,对于残疾患者的高质量护理至关重要,可以避免医源性伤害,改善患者及其护理伙伴的健康和福祉。在这篇文章中,我们回顾了在PWD中使用多种药物的风险,以及在这一人群中使用处方的安全性和有效性的证据。在现有的针对多病和寿命有限的老年人的处方框架的基础上,我们提供了一个针对生活痴呆的独特挑战的PWD处方路线图,包括可变的病程、令人痛苦的行为症状的高患病率以及护理伙伴的核心作用。步骤包括:(1)通过引发药物相关目标并考虑权衡来确定处方的潜在目标,(2)制定逐步减少处方的计划,(3)在处方减少之前完成必要的额外行动,以及(4)提供密切的随访。最后,我们提供了基于证据的策略,用于与患者及其护理伙伴就处方进行沟通,该策略改编自FRAME工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Drugs & Aging
Drugs & Aging 医学-老年医学
CiteScore
5.50
自引率
7.10%
发文量
68
审稿时长
6-12 weeks
期刊介绍: Drugs & Aging delivers essential information on the most important aspects of drug therapy to professionals involved in the care of the elderly. The journal addresses in a timely way the major issues relating to drug therapy in older adults including: the management of specific diseases, particularly those associated with aging, age-related physiological changes impacting drug therapy, drug utilization and prescribing in the elderly, polypharmacy and drug interactions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信